← Back to Search
Other
Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects
Minneapolis, MN
Phase 1
Waitlist Available
Led By Daniel K. Ries, MD
Research Sponsored by Angion Biomedica Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of a single-dose of ANG-3777 in subjects with renal failure receiving maintenance hemodialysis.
See full description
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ANG-3777Experimental Treatment1 Intervention
Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).
Find a Location
Closest Location:Hennepin County Medical Center (HCMC)· Minneapolis, MN
Who is running the clinical trial?
Angion Biomedica CorpLead Sponsor
11 Previous Clinical Trials
946 Total Patients Enrolled
Nucleus Network LtdOTHER
11 Previous Clinical Trials
506 Total Patients Enrolled
Daniel K. Ries, MDPrincipal InvestigatorNucleus Network Ltd
1 Previous Clinical Trials
16 Total Patients Enrolled